DNA X, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
DNA X, Inc. (SONM) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 7.83 thousand shares for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-27.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2024-03-27
- DNA X, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-12-31 was 0.00 shares, a 100.00% decline year-over-year.
- DNA X, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2023-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- DNA X, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-12-31 was 752.00 shares.
- DNA X, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2022-09-30 was 12.02K shares.
- DNA X, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 7.83K shares, a 57.23% decline from fiscal 2022.
- DNA X, Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 18.31K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 0.00 shares derived: sum of 2 quarters · filed 2024-03-27 | 7.83K shares 10-K · filed 2024-03-27 | |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | 7.83K shares 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | 7.83K shares 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | 752.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | 12.78K shares derived: sum of 2 quarters · filed 2024-03-27 | 16.62K shares derived: sum of 3 quarters · filed 2024-03-27 | 18.31K shares 10-K · filed 2024-03-27 |
| 2022-09-30 | 12.02K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | 15.87K shares derived: sum of 2 quarters · filed 2022-11-14 | 17.56K shares 10-Q · filed 2022-11-14 | |
| 2022-06-30 | 3.84K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | 5.54K shares 10-Q · filed 2022-08-12 | ||
| 2022-03-31 | 1.70K shares 10-Q · filed 2022-05-10 | |||
| 2021-09-30 | -35.55K shares derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2022-06-29 | -4.01K shares derived: sum of 2 quarters · filed 2022-06-29 | 13.78K shares 10-Q/A · filed 2022-06-29 | |
| 2021-06-30 | 31.54K shares derived: 10-Q/A 6 month − 10-Q 3 month · filed 2022-06-29 | 49.33K shares 10-Q/A · filed 2022-06-29 | ||
| 2021-03-31 | 17.79K shares 10-Q · filed 2021-05-11 | |||
| 2020-09-30 | 35.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | 114.06K shares 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | 79.01K shares 10-Q · filed 2020-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CLEARONE INC (CLRO) | United States | $0.009B | |
| FRANKLIN WIRELESS CORP (FKWL) | United States | $0.028B | -61.80 |
| FiEE, Inc. (FIEE) | Japan | $0.033B | 8.06 |
| Clearfield, Inc. (CLFD) | United States | $0.415B | -74.88 |
| ADTRAN Holdings, Inc. (ADTN) | United States | $0.565B | -43.25 |
| Fabrinet (FN) | $14.287B | 39.79 | |
| CIENA CORP (CIEN) | United States | $50.874B | 81.72 |